BioSpace News Archive

Join journalists from around the world covering the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting March 17-21, 2020 in San Antonio, TX

Marubeni Corporation and Optina Diagnostics agreed to enter into a market development partnership to bring Optina’s early dementia diagnosis platform to the Japanese market.

Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal, will present a corporate overview at the 12th Annual LD Micro Main Event on Tuesday,

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 2019 Cross-Border Healthcare Winter Summit on Tuesday, December 10, 2019

Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has completed development of its ECG patch platform.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company will be presenting at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) to be held in Hollywood, FL, December 8-11, 2019.

Innovative Cellular Therapeutics (ICT), a biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for blood cancers and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ICTCAR014, a next generation CD19-targeting CAR-T cell therapy that expresses a dominant negative PD-1 protein to block immunosuppression by cancer cells

Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an orally inhaled benzodiazepine for the acute termination of an ongoing prolonged focal, generalized or cluster seizure episode in patients who experience breakthrough seizures while on an antiepileptic drug, today announced two poster presentations at the American Epilepsy Society’s Annual Meeting (AES 2019), which is being held Dec. 6-10,

Washington, D.C., Leads the Nation with Nearly 50% of E-Prescribers Utilizing the Technology

Providing virtual access to nutrition services as part of the Teladoc Health comprehensive continuum of care will further optimize long-term health outcomes and ultimately reduce overall medical costs, particularly for those individuals with existing chronic and complicated health conditions.